The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes

Oncologist

Volumn 18, Issue 5, 2013, Pages 493-500

  Bayraktar, Soley ^a   Thompson, Patricia A ^b   Yoo, Suk Young ^c   Do, Kim Anh ^c   Sahin, Aysegul A ^c   Arun, Banu K ^c   Bondy, Melissa L ^c   Brewster, Abenaa M ^d  

^a Mercy Cancer Center   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

17q23; Breast cancer; Prognosis; Single nucleotide polymorphisms; TNRC9

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

17Q23; BREAST CANCER; PROGNOSIS; SINGLE-NUCLEOTIDE POLYMORPHISMS; TNRC9;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84878165328     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0419     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. National Cancer Institute. SEER Cancer Statistics Review. Available at http://seer.cancer.gov/csr/1975_2009_pops09/index.html. Accessed February 27, 2013.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:Anoverview of the randomised trials. Lancet 2005;365:1687-1717.
4. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001;27:234-236.
5. Easton DF, Pooley KA, Dunning AM et al. Genome- wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447: 1087-1093.
6. Thomas G, Jacobs KB, Kraft P et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009;41:579-584.
7. Han J, Kraft P, Nan H et al. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008; 4:e1000074.
8. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007;39:865-869.
9. Gold B, Kirchhoff T, Stefanov S et al. Genomewide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A 2008;105:4340-4345.
10. Zheng W, Long J, Gao YT et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009;41: 324-328.
11. Ahmed S, Thomas G, Ghoussaini M et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009;41:585-590.
12. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008;40:703-706.
13. Cox A, Dunning AM, Garcia-Closas M et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-358.
14. Dunning AM, Healey CS, Baynes C et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009;18:1131-1139.
15. Pharoah PD, Antoniou A, Bobrow M et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-36.
16. Peng S, Lu B, Ruan W et al. Genetic polymorphisms and breast cancer risk: Evidence from metaanalyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat 2011; 127:309-324.
17. Azzato EM, Lee AJ, Teschendorff A et al. Common germ-line polymorphism of C1QA and breast cancer survival. Br J Cancer 102:1294-1299.
18. Bachmann HS, Otterbach F, Callies R et al. The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res 2007;13:5790-5797.
19. Kasimir-Bauer S, Heubner M, Otterbach F et al. Prognostic relevance of the AQP5-1364C>A polymorphism in primary breast cancer. Mol Med Report 2009;2:645-650.
20. Brendle A, Brandt A, Johansson R et al. Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: A Swedish prospective case-control study. Eur J Cancer 2009;45:435-442.
21. Gaudet MM, Hunter K, Pharoah P et al. Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. Int J Cancer 2009;124:1716-1720.
22. Hughes S, Agbaje O, Bowen RL et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res 2007;13:6673-6680.
23. Long JR, Kataoka N, Shu XO et al. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 2006; 15:2115-2122.
24. Otterbach F, Callies R, Frey UH et al. The T393C polymorphism in the gene GNAS1 ofGprotein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat 2007; 105:311-317.
25. Papadopoulou E, Tripsianis G, Anagnostopoulos K et al. Significance of serum tumor necrosis factor- alpha and its combination with HER-2 codon 655polymorphismin the diagnosisandprognosis of breast cancer. Int J Biol Markers 2010;25:126-135.
26. Qu S, Long J, Cai Q et al. Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res 2008;14: 4787-4793.
27. Udler MS, Azzato EM, Healey CS et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 2009;125:2687-2696.
28. Varadi V, Bevier M, Grzybowska E et al. Genetic variation in genes encoding for polymerase zeta subunits associates with breast cancer risk, tumour characteristics and survival. Breast Cancer Res Treat 2011;129:235-245.
29. Shu XO, Long J, Lu W et al. Novel genetic markers of breast cancer survival identified by agenomewide association study. Cancer Res 2012;72:1182-1189.
30. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
31. Brewster AM, Do KA, Thompson PA et al. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 2007;25: 4438-4444.
32. Chen MBWX, Shen W et al. Association between polymorphisms of trinucleotide repeat containing9geneandbreast cancer risk: Evidence from 62,005 subjects. Breast Cancer Res Treat 2011;126: 177-183.
33. QIAamp DNA Mini and Blood Mini Handbook. Available at http://dna.uga.edu/docs/QIAamp_DNA_Mini_and_Blood_Mini_Handbook%20(Qiagen).pdf. Accessed February 27, 2013.
34. Applied Biosystems Arcturus PicoPure DNA Extraction Kit. Available at: http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_086335.pdf. Accessed April 25, 2013.
35. Bender R, Lange S. Adjusting for multiple testing: When and how? J Clin Epidemiol 2001;54:343-349.
36. Liang J, Chen P, Hu Z et al. Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population. Breast Cancer Res Treat 2010;124:237-241.
37. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH et al. Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 2007;9:R78.
38. Reeves GK, Travis RC, Green J et al. Incidence of breast cancer and its subtypes in relation to individualandmultiple low-penetrance genetic susceptibility loci. JAMA 2010;304:426-434.
39. Li L, Zhou X, Huang Z et al. TNRC9/LOC643714 polymorphisms are not associated with breast cancer risk in Chinese women. Eur J Cancer Prev 2009; 18:285-290.
40. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-872.
41. Stranger BE, Nica AC, Forrest MS et al. Population genomics of human gene expression. Nat Genet 2007;39:1217-1224.
42. Broeks A, Schmidt MK, Sherman ME et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: Findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011;20:3289-3303.
43. Ding S, Yu JC, Chen ST et al. Diverse associations between ESR1 polymorphism and breast cancer development and progression. Clin Cancer Res 2010;16:3473-3484.
44. Hsieh S, Look MP, Sieuwerts AM et al. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: A prognosis study. Breast Cancer Research 2009;11:R75.
45. Lei H, Hemminki K, Johansson R et al. PAI-1-675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat 2008;109:165-175.
46. Chrisanthar R, Knappskog S, Lokkevik E et al. Predictiveandprognostic impact ofTP53mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 6:e19249.
47. Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
48. Colomer R, Monzo M, Tusquets I et al. Asinglenucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-816.
49. Smid M, Wang Y, Klijn JG et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006;24:2261-2267.
50. Andersen CL, Monni O, Wagner U et al. Highthroughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol 2002;161: 73-79.
51. Barlund M, Forozan F, Kononen J et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000;92:1252-1259.
52. Isola JJ, Kallioniemi OP, Chu LW et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. AmJ Pathol 1995;147:905-911.
53. Inaki K, Hillmer AM, Ukil L et al. Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res 2011;21:676-687.
54. Azzato EM, Pharoah PD, Harrington P et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev 2010;19:1140-1143.